The conversation discusses Scube3, a seemingly new and obscure treatment for hair loss, with limited information available and a link to a patient intake form.
The conversation discusses how Tretinoin may improve the effectiveness of Minoxidil for treating hair loss by increasing the activity of certain enzymes in hair follicles. One user comments that this information is not new.
The conversation discusses the lack of public information on the chemical structure of PP405, a hair loss treatment, and the challenges of synthesizing it without a patent. It also explores a patent related to hydrogen-based topical formulations for reducing oxidative stress and inflammation.
Hair loss treatments, specifically the use of oral minoxidil in combination with micro-needling. Oral minoxidil has been found to improve hair density in 90% of patients with a low side effect profile, but using 5mg per day can result in higher side effects including hypertrichosis and edema. Other treatments mentioned include finasteride and RU58841.
User has itching, dandruff, and scalp issues, considering Nizoral 1% shampoo for treatment. Nizoral's effectiveness for hair loss is uncertain due to limited research, short contact time, and concentration differences.
Kintor Pharma has finished enrolling the first patient in a Phase III trial for KX-826, a treatment for androgenetic alopecia (AGA). One user has set a reminder to check back on the topic in a year.
A 34-year-old male shares his hair regrowth journey using Minoxidil Max Dual Gen with topical finasteride, hair oil, derma rolling, and nizoral shampoo, emphasizing persistence and consistency. Despite some skepticism about lighting and treatment effectiveness, he reports significant progress over 12 months.
Oral minoxidil treatment increased hair density and shaft caliber in AGA patients. Side effects included hypertrichosis and lower extremity edema, with younger patients experiencing fewer side effects.
A dermatologist advised a patient to stop taking finasteride (fin) after turning 40 due to potential risk of aggressive prostate cancer. The patient and others in the conversation debated this advice, discussing the relationship between finasteride, prostate cancer, and hair loss, and considering alternatives like topical finasteride.
A 19-year-old is frustrated with doctors giving misleading information about hair loss treatments, specifically finasteride and minoxidil. They plan to self-administer finasteride due to concerns about side effects and lack of supportive medical guidance.
Doctors in Denmark and other countries often lack knowledge about hair loss treatments like Finasteride and Dutasteride, causing patients to seek prescriptions from multiple doctors or online. Some users report better experiences in countries like Brazil and Korea, where doctors are more informed and willing to prescribe these medications.
People discuss whether it's appropriate to suggest hair loss treatments like finasteride or minoxidil to others, especially young individuals. Opinions vary, with some advocating for sharing information and others cautioning against unsolicited advice due to potential side effects and personal sensitivities.
KX-826 combined with minoxidil significantly increases hair growth compared to minoxidil alone for treating male androgenetic alopecia, with no unexpected safety concerns. Users discuss various hair loss treatments, including KX-826, minoxidil, finasteride, and RU58841, sharing personal experiences and sourcing information.
Avoiding excessive time on hair loss forums to reduce anxiety and focus on consistent use of treatments like finasteride and minoxidil. Users emphasize trusting medical advice, being patient for results, and not overanalyzing anecdotal experiences.
The user has been on dutasteride for six months and experienced significant hair shedding, especially at the hairline, and is seeking advice. Some suggest continuing the treatment and being patient, while others share mixed experiences with dutasteride and consider switching back to finasteride or adding other treatments like RU58841.
The Phase 2 trial for Pyrilutamide in the US, which started a year after the China trials, and inquiring about any available information on when it will finish. Treatments discussed include Minoxidil, Finasteride, and RU58841.
PP405 is considered a potential new treatment for hair loss, compared to finasteride and minoxidil. There is skepticism about its effectiveness in humans, with anticipation for more information from an upcoming conference.
Pyrilutamide, a possible hair loss treatment, ceasing to be traded due to patent laws; and the hope that this indicates it may be a legitimate treatment.
The user shared their experience with hair loss treatments, including low-dose minoxidil, finasteride, and essential oils, and expressed concerns about the cognitive side effects of finasteride. They are seeking more information on how finasteride may affect cognition and are considering whether to continue or stop the treatment.
Treatments for hair loss, including microneedling (dermarolling and dermapen) and the use of minoxidil, finasteride, and RU58841. It provides detailed information about cost and usage of the various treatments, as well as potential side effects.
Hair regrowth treatments like Minoxidil and Finasteride take a long time, often up to a year, to show significant results, and people should be patient. Many users express frustration with unrealistic expectations for quick results and emphasize the importance of consistency and patience.
Finasteride and minoxidil are discussed as hair loss treatments, with mixed opinions on side effects like sexual dysfunction and mood changes. Some users report positive results, while others express concerns about potential risks and insufficient information.
The conversation is about the side effects of finasteride, including Post Finasteride Syndrome, with varied personal experiences and differing views on the credibility of information sources. Some participants also discuss using minoxidil as a hair loss treatment.
A compounding pharmacist offers affordable topical finasteride foam with Anagain and micro-dose finasteride capsules for hair loss. They provide telehealth services across Canada and private appointments for international patients.
PP405 is moving to late-stage trials, showing potential for hair regrowth, with 31% of male patients experiencing a 20% increase in hair density. Veradermics is developing an oral minoxidil version, and there is interest in combining treatments for better results.
A new hair loss treatment, PP405, showed promising Phase 2a results with 31% of patients experiencing over 20% hair density increase without systemic absorption, avoiding hormonal side effects. The treatment is expected to be expensive, with Phase 3 trials starting mid-2026, and there is skepticism about the data's strength.
RU58841 is a controversial hair loss treatment with mixed reviews; some users report success, often in combination with other treatments like finasteride or minoxidil, while others experience side effects like chest pain. The treatment's discontinuation is speculated to be due to patent expiration and lack of profitability, despite some users continuing to use it as part of a broader regimen.
Hair loss treatments, specifically, discussing the effectiveness and side effects of finasteride, minoxidil, and RU58841 in various microdoses. It also includes an updated graph which provides information on how different doses affect DHT levels, scalp skin and serum androgen levels, as well as hair count.